Outlook Therapeutics Inc. (NASDAQ: OTLK) has confirmed that it will release its Q4 2021 earnings on Wednesday, December 22, 2021.
What to look for
The firm has begun initiatives such as drug substance manufacture with FUJIFILM Diosynth Biotechnology in preparation for the commercial launch of ONS-5010 in 2022. Furthermore, outlook Therapeutics is preparing registration documents for regulatory clearance in Europe via a separate route and will submit them after completing FDA submissions with the US FDA.
Earnings: Stockearning’s estimated EPS for Q4 2021 is expected to be around $0.09 per share. In the third quarter, the company reported a net loss attributable to shareholders of $12.2 million or $0.07 per basic share. For the third quarter of 2021, the company had a net loss of $0.03 per share. Historical EPS Performance shows that the company has in the past 12 quarters beat estimates five times (45%) and missed estimates once (9%).
Revenue: At the end of the third quarter, the company had cash and investments of around $19.7 million. The company's cash is adequate to run its planned operations through December 2021.
Stock movement: Outlook Therapeutics shares have lost 45.1% since the company released Q3 2021 earnings. However, following the earnings release, the company's shares have been UP six times in the last 12 quarters. So, the historical price reaction suggests a 50% probability of the share price going UP once Outlook Therapeutics reports its fiscal Q4 2021 quarterly earnings. According to the Stockearning algorithm, the predicted first-day move is 6%, while the predicted move on the seventh day is 28%.
What analysts are saying
Brookline Capital Markets analyst Kumaraguru Raja raised his price target in Outlook Therapeutics from $5 to $8 but maintained a “Buy” rating. The analyst said, “A new biologics license application (BLA) submission, under the PHSA 351(a) regulatory pathway, for wet AMD is planned in the calendar first quarter of 2022. Outlook is also working on filing for approval in Europe in 2022. We are increasing our estimates and our probability of success to 95%.”
H.C. Wainwright analyst Douglas Tsao reiterated his “buy” rating on the stock but raised his target price for the shares from $5 to $6. Outlook Therapeutics announced exceptional data showing Lytenava's statistically significant superiority over Lucentis in subjects with more than or equal to 15 letters corrected visual acuity and average BCVA score gain in both intent to treat and according to protocol populations per Tsao’s research note to investors. According to the analyst, the 18% response rate differential leaves no doubt about Lytenava's performance. Tsai also raised the drug's chances of being successful in wet macular degeneration to roughly 80%.
Related News
Micron Technology Inc. (NASDAQ:MU) Earnings Expectation, Fiscal Q1 2022 EPS of $2.1
Outlook Therapeutics Inc. (NASDAQ: OTLK) Earnings Expectation, Loss Per Share of $0.09 in Q4 2021